ROADMAP launches 3-dimensional landscape of European data availability for Alzheimer’s disease research

ROADMAP launches 3-dimensional landscape of European data availability for Alzheimer’s disease research

 

Monday, 13 May, 2019

The Real world Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform (ROADMAP) project is proud to announce the public launch of its Data Cube, which allows a dynamic overview of the “landscape” of data availability in Europe for Alzheimer’s disease (AD) research.

The project was funded through the Innovative Medicines Initiative, and brought together 26 organisations led by Novartis and coordinated by the University of Oxford. Prof Catherine Sudlow (Director, Centre for Medical Informatics) is one of the collaborators in this project.

The consortium developed a 3D “heat map” assessment which allows the visualisation of the different data sources and how they are able to capture different AD outcomes together with their relevance for the different disease stages. When navigating this landscape, users can switch between the perspectives of people with dementia, carers, and health professionals.

Through the Data Cube, ROADMAP aims to help address the challenge of how best to inform clinical and health-policy decisions by studying how to build a population-based integrated data environment and enabling its visualisation. Dr Catherine Reed, Principal Research Scientits, Eli Lilly and Company, says, “For scientists and researchers, the Data Cube is a unique way to view available outcomes data and identify useful data sources for disease modelling as well as opportunities for further research in the evidence gaps identified.”